FDA grants priority review for Genentech’s cervical cancer therapy
The US Food and Drug Administration (FDA) has accepted Roche subsidiary Genentech's supplemental biologics licence application (sBLA) and granted priority review for Avastin plus chemotherapy for treatment of women with persistent, recurrent or metas…
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Cancer Therapy | Cervical Cancer | Chemotherapy | Food and Drug Administration (FDA) | Grants | Pharmaceuticals | Women